- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02350153
Cushing´s Disease Epidemiology in Sweden
National Swedish Study in Cushing´s Disease Incidence and Outcomes
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This study is a retrospective nationwide study of all patients in Sweden with diagnosis CD between 1987 and 2013 were baseline data at diagnosis, information about the different treatments and follow-up data is going to be obtained by reviewing patients' medical journals. This information as well as the exact diagnose criteria for each patient are going to be extracted by Endocrinologists in all University Hospitals in Sweden. An expert group at the Sahlgrenska University Hospital in Gothenburg will put together the data.By the use of the Swedish Personal Number, the investigators are going to obtain information about both patients' and background population co-morbidities which have been collected in the different Swedish Registers.
Primary aim:
To study mortality of CD in Sweden.
Secondary aims:
- To study the influence of CD on myocardial infarction
- To study the influence of CD on stroke
- To study the influence of CD on cancer
- To study the influence of CD on hip fracture risk
- To study incidence and prevalence of CD in Sweden.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Vastra Gotaland Region
-
Gothenburg, Vastra Gotaland Region, Schweden, 413 45
- Sahlgrenska University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- All patients registered with Cushing's Disease in Sweden since 1987 in the statistical database for in- and out-patients, at the Swedish National Board of Health and Welfare will be included in the study.
Exclusion Criteria:
- No
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
---|
Patients with verified Cushing's Disease
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Mortality
Zeitfenster: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
If event (death) has been occured during the observation period.
Data obtained by the Swedish Cause Of Death Register (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
influence of Cushing's Disease on myocardial infarction
Zeitfenster: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (myocardial infarction) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
influence of Cushing's Disease on stroke
Zeitfenster: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (stroke) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
influence of Cushing's Disease on cancer
Zeitfenster: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (cancer) has been occured during the observation period.Data obtained by the Swedish Register of Cancer Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
influence of Cushing's Disease on hip fracture risk
Zeitfenster: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (hip fracture) has been occured during the observation period.Data obtained by the Swedish Register of Hip Fractures (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
incidence of Cushing's Disease in Sweden
Zeitfenster: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
prevalence of Cushing's Disease in Sweden
Zeitfenster: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Gudmundur Johannsson, Professor, Vastra Gotaland Region, Sahlgrenska University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Neubildungen, Drüsen und Epithelien
- Erkrankungen des endokrinen Systems
- Neoplasmen der endokrinen Drüse
- Hypothalamische Erkrankungen
- Hyperpituitarismus
- Hypophysenerkrankungen
- Adenom
- Hypophysentumoren
- ACTH-sezernierendes Hypophysenadenom
- Hypophysäre ACTH-Hypersekretion
Andere Studien-ID-Nummern
- NSSCDIO
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Cushing-Krankheit
-
Sheffield Teaching Hospitals NHS Foundation TrustHRA PharmaAbgeschlossenSubklinisches CushingVereinigtes Königreich
-
University of MichiganRecordati Rare DiseasesRekrutierungNebennieren-Insuffizienz | Hyperkortisolismus | Endogenes Cushing-SyndromVereinigte Staaten
-
RECORDATI GROUPRekrutierungEndogenes Cushing-SyndromVereinigte Staaten, Deutschland, Frankreich
-
Corcept TherapeuticsAbgeschlossen
-
Sparrow PharmaceuticalsAktiv, nicht rekrutierendAutonome Cortisol-Sekretion (ACS) | ACTH-unabhängiges Cushing-Syndrom | ACTH-unabhängiges Nebennieren-Cushing-Syndrom, somatischVereinigte Staaten, Rumänien, Vereinigtes Königreich
-
Centre hospitalier de l'Université de Montréal...Recordati Rare DiseasesAktiv, nicht rekrutierendEndogenes Cushing-SyndromKanada
-
Cortendo ABAbgeschlossenEndogenes Cushing-SyndromVereinigte Staaten, Bulgarien, Dänemark, Frankreich, Griechenland, Ungarn, Israel, Italien, Niederlande, Polen, Rumänien, Spanien
-
Wuerzburg University HospitalAbgeschlossenHerz-Kreislauf-Status bei Patienten mit endogenem Cortisol-Überschuss (Cushing-Syndrom) (CV-CORT-EX)Endogenes Cushing-SyndromDeutschland
-
Cortendo ABAbgeschlossenEndogenes Cushing-SyndromVereinigte Staaten, Serbien, Dänemark, Italien, Spanien, Polen, Belgien, Bulgarien, Kanada, Tschechien, Frankreich, Deutschland, Israel, Niederlande, Truthahn
-
Andrea M. IsidoriAbgeschlossenCushing-Syndrom-KardiomyopathieItalien